Ellagic acid microspheres restrict the growth of Babesia and Theileria in vitro and Babesia microti in vivo

Parasit Vectors. 2019 May 28;12(1):269. doi: 10.1186/s13071-019-3520-x.

Abstract

Background: There are no effective vaccines against Babesia and Theileria parasites; therefore, therapy depends heavily on antiprotozoal drugs. Treatment options for piroplasmosis are limited; thus, the need for new antiprotozoal agents is becoming increasingly urgent. Ellagic acid (EA) is a polyphenol found in various plant products and has antioxidant, antibacterial and effective antimalarial activity in vitro and in vivo without toxicity. The present study documents the efficacy of EA and EA-loaded nanoparticles (EA-NPs) on the growth of Babesia and Theileria.

Methods: In this study, the inhibitory effect of EA, β-cyclodextrin ellagic acid (β-CD EA) and antisolvent precipitation with a syringe pump prepared ellagic acid (APSP EA) was evaluated on four Babesia species and Theileria equi in vitro, and on the multiplication of B. microti in mice. The cytotoxicity assay was tested on Madin-Darby bovine kidney (MDBK), mouse embryonic fibroblast (NIH/3T3) and human foreskin fibroblast (HFF) cell lines.

Results: The half-maximal inhibitory concentration (IC50) values of EA and β-CD EA on B. bovis, B. bigemina, B. divergens, B. caballi and T. equi were 9.58 ± 1.47, 7.87 ± 5.8, 5.41 ± 2.8, 3.29 ± 0.42 and 7.46 ± 0.6 µM and 8.8 ± 0.53, 18.9 ± 0.025, 11 ± 0.37, 4.4 ± 0.6 and 9.1 ± 1.72 µM, respectively. The IC50 values of APSP EA on B. bovis, B. bigemina, B. divergens, B. caballi and T. equi were 4.2 ± 0.42, 9.6 ± 0.6, 2.6 ± 1.47, 0.92 ± 5.8 and 7.3 ± 0.54 µM, respectively. A toxicity assay showed that EA, β-CD EA and APSP EA affected the viability of cells with a half-maximal effective concentration (EC50) higher than 800 µM. In the experiments on mice, APSP EA at a concentration of 70 mg/kg reduced the peak parasitemia of B. microti by 68.1%. Furthermore, the APSP EA-atovaquone (AQ) combination showed a higher chemotherapeutic effect than that of APSP EA monotherapy.

Conclusions: To our knowledge, this is the first study to demonstrate the in vitro and in vivo antibabesial action of EA-NPs and thus supports the use of nanoparticles as an alternative antiparasitic agent.

Keywords: APSP EA; Babesia; Ellagic acid; Nanoparticles; Theileria; β-cyclodextrin ellagic acid.

MeSH terms

  • Animals
  • Antiprotozoal Agents / pharmacology*
  • Babesia / drug effects*
  • Babesia / growth & development
  • Babesia microti / drug effects*
  • Babesiosis / drug therapy
  • Cattle
  • Cell Line
  • Ellagic Acid / pharmacology*
  • Female
  • Fibroblasts / drug effects
  • Fibroblasts / parasitology
  • Humans
  • Inhibitory Concentration 50
  • Mice
  • Mice, Inbred BALB C
  • Nanoparticles / chemistry
  • Plant Extracts / pharmacology
  • Theileria / drug effects*
  • Theileria / growth & development
  • Theileriasis / drug therapy

Substances

  • Antiprotozoal Agents
  • Plant Extracts
  • Ellagic Acid